KR20190139521A - A Composition Comprising Extract of Enteromorpha for promoting muscle tissue production - Google Patents

A Composition Comprising Extract of Enteromorpha for promoting muscle tissue production Download PDF

Info

Publication number
KR20190139521A
KR20190139521A KR1020180066105A KR20180066105A KR20190139521A KR 20190139521 A KR20190139521 A KR 20190139521A KR 1020180066105 A KR1020180066105 A KR 1020180066105A KR 20180066105 A KR20180066105 A KR 20180066105A KR 20190139521 A KR20190139521 A KR 20190139521A
Authority
KR
South Korea
Prior art keywords
extract
muscle tissue
composition
green
tissue production
Prior art date
Application number
KR1020180066105A
Other languages
Korean (ko)
Other versions
KR102082196B1 (en
Inventor
남택정
최정욱
전정임
Original Assignee
부경대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 부경대학교 산학협력단 filed Critical 부경대학교 산학협력단
Priority to KR1020180066105A priority Critical patent/KR102082196B1/en
Publication of KR20190139521A publication Critical patent/KR20190139521A/en
Application granted granted Critical
Publication of KR102082196B1 publication Critical patent/KR102082196B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • A61K36/05Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a composition for promoting muscle tissue production containing an enteromorpha extract. When taking the enteromorpha extract of the present invention, an effect of promoting muscle tissue production is exhibited. The enteromorpha extract of the present invention has the effect of promoting muscle tissue production, it is suitable to be used as the composition for promoting muscle tissue production.

Description

파래 추출물을 포함하는 근조직 생성 촉진용 조성물{A Composition Comprising Extract of Enteromorpha for promoting muscle tissue production}A composition comprising extract of enteromorpha for promoting muscle tissue production}

본 발명은 파래 추출물을 포함하는 근조직 생성 촉진용 조성물에 관한 것이다.The present invention relates to a composition for promoting muscle tissue production, including a green leaf extract.

현재 대한민국은 급격한 속도로 고령화 시대로 전환되어지고 있으며, 2017년 65세 이상 인구는 707만명으로 전체 인구의 13.8%를 차지하는 것으로 나타났다. 최근 연구결과를 살펴보았을 때 연령이 증가함에 따라 근육이 감소하는 근감소증이 나타나는 경향이 증가한다는 사실이 보고되고 있으며, 이러한 근육량의 감소 및 근력 약화는 체력 약화와 활동성의 저하로 이어지고, 최종적으로 독립된 생활이 어렵게 만드며, 부가적으로는 신체장애를 야기한다. 또한 근감소는 당뇨, 비만, 고혈압의 성인병과 퇴행성 질환으로 이어질 수 있기 때문에 근감소는 노령화 시대의 잠재적 위험 요인으로 인식되고 있다. The Republic of Korea is rapidly shifting to an aging age, and in 2017, the number of people aged 65 or over was 707 million, accounting for 13.8% of the total population. Recent studies have shown that as muscle age decreases, muscle tendency to decrease muscles tends to increase, and such decreases in muscle mass and muscle strength lead to weakness and weakness, and finally to independent activity. It makes life difficult and additionally causes physical disability. In addition, muscle reduction is recognized as a potential risk factor in an aging age because it can lead to adult disease and degenerative diseases of diabetes, obesity and hypertension.

한편, 파래는 해조류 중 녹조류 일종으로 향기가 많고 맛이 독특하여 한국과 일본 등지에서 즐겨 먹는 해조류의 한 종류로서 칼륨, 미네랄 성분이 풍부한 것으로 알려져 있으며, 파래에서 추출된 다당류에는 혈중 지질 감소, 항박테리아, 항염증 그리고 항암활성이 있는 것으로 보고되고 있다(Wang et al). 이와 관련 파래 성분을 분리 및 정제하여 그 약리작용 및 작용기전을 밝혀내는 연구도 다양하게 진행 중이다. On the other hand, green seaweed is a kind of green algae among seaweeds, and it is known to be rich in potassium and minerals as it is a kind of algae that is enjoyed in Korea and Japan, and the polysaccharides extracted from the seaweed have reduced blood lipid and antibacterial. , Anti-inflammatory and anticancer activity have been reported (Wang et al). Various studies have been conducted to isolate and purify the related green component to reveal its pharmacological action and mechanism of action.

이에 본 발명의 목적은 파래 추출물을 포함하는 근조직 생성 촉진용 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition for promoting muscle tissue production, including green extract.

본 발명의 발명자는 파래 추출물이 근조직의 생성을 촉진 할 수 있다는 것을 밝혀내어 본 발명을 완성하였다. 따라서 본 발명의 과제 해결 수단은 파래 추출물을 포함하는 근조직 생성 촉진용 조성물이다.The inventors of the present invention have found that the green extract can promote the production of muscle tissue to complete the present invention. Therefore, the problem solving means of the present invention is a composition for promoting the production of muscle tissue containing the green extract.

본 발명의 파래 추출물은 근조직의 생성을 촉진하는 효과를 가지는 바, 근조직 생성 촉진용 조성물로 사용되기에 적합하다.The green extract of the present invention has an effect of promoting the production of muscle tissue, it is suitable to be used as a composition for promoting muscle tissue production.

도 1은 본 발명의 파래 추출물을 제조하기 위한 추출 과정을 간략화한 도이다.
도 2는 본 발명의 파래 추출물과 비교예로 사용된 파래 증류수 추출물의 세포 활성 측정을 나타낸 것이다.
도 3은 본 발명의 파래 추출물을 처리한 경우 나타나는 IGF-1 신호경로 활성화의 측정 결과를 나타낸 것이다.
도 4는 본 발명의 파래 추출물을 처리한 경우 나타나는 MEK 신호경로 활성화의 측정 결과를 나타낸 것이다.
Figure 1 is a simplified diagram of the extraction process for producing the green extract of the present invention.
Figure 2 shows the cell activity measurement of the green distilled water extract used as a comparative example with the green extract of the present invention.
Figure 3 shows the results of the measurement of IGF-1 signaling pathway activation when treated with the green extract of the present invention.
Figure 4 shows the measurement results of the MEK signal pathway activation when treated with the green extract of the present invention.

본 발명은 파래 추출물을 포함하는 근조직 생성 촉진용 조성물을 제공한다.The present invention provides a composition for promoting muscle tissue production, including the green extract.

상기 파래 추출물은 1) 파래를 증류수로 추출하는 것;The seaweed extract is 1) extracting the seaweed with distilled water;

2) 상기 추출물을 원심분리하여 상층액을 분리하는 것;2) separating the supernatant by centrifuging the extract;

3) 상기 상층액에 2 내지 4배 부피의 에탄올을 가하고 당을 가라앉히는 것; 및 3) adding 2-4 times the volume of ethanol to the supernatant to settle the sugar; And

4) 가라앉힌 당을 여과하여 제거한 후 여과액을 감압 농축하는 것을 포함하는 방법으로 수득된다.4) It is obtained by a method comprising filtration of the settled sugar and then concentration of the filtrate under reduced pressure.

상기 1) 단계에서의 파래는 파래 분말인 것이 바람직하다.The green sea in the step 1) is preferably a green powder.

상기 1) 단계에서의 증류수는 파래 분말 중량의 20 내지 30배 사용하는 것이 바람직하다. 이보다 적게 사용할 경우, 유효 성분이 제대로 추출되지 않을 수 있으며, 이보다 많게 사용할 경우 전체 추출 과정에 사용되는 비용이 상승하는 문제점이 있다.Distilled water in the step 1) is preferably used 20 to 30 times the weight of the green powder. If less than this, the active ingredient may not be extracted properly, if more than this there is a problem that the cost used for the entire extraction process increases.

상기 3) 단계에서의 에탄올은 상층액 부피의 2 내지 4배 사용하는 것이 바람직하다. 이보다 적게 사용할 경우, 유효 성분이 제대로 추출되지 않을 수 있으며, 이보다 많게 사용할 경우 전체 추출 과정에 사용되는 비용이 상승하는 문제점이 있다. Ethanol in step 3) is preferably used 2 to 4 times the volume of the supernatant. If less than this, the active ingredient may not be extracted properly, if more than this there is a problem that the cost used for the entire extraction process increases.

본 발명의 상기 추출 방법은 5) 얻어진 추출물을 증류수에 녹이고 암모늄 설페이트를 첨가하여 침전물을 수득하는 것을 더 포함할 수 있다.The extraction method of the present invention may further comprise 5) dissolving the obtained extract in distilled water to obtain a precipitate by adding ammonium sulfate.

상기 암모늄 설페이트는 파래 추출물을 침전시키기 위한 목적으로 상용되며, 암모늄 설페이트 이외에 아세톤이 사용 가능하다.The ammonium sulfate is commercially available for the purpose of precipitating the greenish extract, acetone may be used in addition to the ammonium sulfate.

본 발명의 파래 추출물은 근조직 생성 촉진 효과를 나타내어 근조직 생성 촉진용 조성물로 사용되기에 적합하다.The green extract of the present invention is suitable for being used as a composition for promoting muscle tissue production by showing the effect of promoting muscle tissue production.

본 발명의 근조직 생성 촉진용 조성물은 파래 추출물 이외에 근조직 생성 촉진 효과를 갖는 다른 성분을 더 포함할 수 있다.The composition for promoting muscle tissue production of the present invention may further include other components having a muscle tissue production promoting effect in addition to the green extract.

본 발명의 근조직 생성 촉진용 조성물은 일반적으로 약물에 포함될 수 있는 담체, 부형제 및 희석제를 포함할 수 있고, 사용될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에이스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐리롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 및 광물유를 들 수 있다.The composition for promoting muscle tissue production of the present invention may include carriers, excipients and diluents that can be included in the drug in general, and the carriers, excipients and diluents that can be used include lactose, dextrose, sucrose, sorbitol, mannitol , Xylitol, Aceritol, Maltitol, Starch, Acacia Rubber, Alginate, Gelatin, Calcium Phosphate, Calcium Silicate, Cellulose, Methyl Cellulose, Microcrystalline Cellulose, Polyvinyrrolidone, Water, Methylhydroxybenzoate, Propylhydroxybenzo Eight, talc, magnesium stearate, and mineral oil are mentioned.

상기 근조직 생성 촉진용 조성물을 제제화하는 경우 일반적으로 사용되는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등을 포함할 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘카보네이트(calcium carbonate), 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구 투여를 위한 액상 제제로는 현탁액, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 웨텝솔(witepsol), 마크로골, 트윈(tween)61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.When formulating the composition for promoting muscle tissue production, it may include fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like that are generally used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. Or it may be prepared by mixing lactose (lactose), gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solvents, emulsions, and syrups, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

또한 본 발명의 근조직 생성 촉진용 조성물은 근조직 손상 치료에 사용되는 종래의 다른 약물과 병용하여 사용할 수 있다. 종래의 다른 약물과 병용하는 경우, 순차적으로 혹은 동시에 투여될 수 있으며, 이는 통상의 기술자에게 용이하게 결정될 수 있다.In addition, the composition for promoting muscle tissue production of the present invention can be used in combination with other conventional drugs used to treat muscle tissue damage. When used in combination with other conventional drugs, they may be administered sequentially or simultaneously, which can be readily determined by one skilled in the art.

본 발명의 근조직 생성 촉진용 조성물은 본 발명의 목적에 부합하는 범위 내에서 어떠한 일반적인 경로를 통해서도 투여될 수 있다. 본 발명의 조성물은 목적하는 바에 따라 복강내 투여, 정맥내 투여, 근육내 투여, 피하 투여, 피내 투여, 경구 투여, 비내 투여, 폐내 투여, 직장내 투여될 수 있으나, 이에 제한되지는 않는다. 또한 상기 조성물은 활성 물질이 표적 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다.The composition for promoting muscle tissue production of the present invention can be administered via any general route within the scope consistent with the object of the present invention. The composition of the present invention may be administered as desired, but is not limited to intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, pulmonary administration, rectal administration. The composition may also be administered by any device in which the active agent may migrate to the target cell.

실시예Example

이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 이에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited thereto.

파래 분말의 제조Preparation of Laver Powder

부산 근해에서 채취한 파래를 깨끗한 물에 3 내지 4회 수세하여 염분 및 불순물을 제거하고, 수세, 정선 및 탈수의 과정을 거쳐 동결 건조기로 건조한 후 식품 분쇄기로 분말화하여 파래 분말을 제조하였다.Seagrass collected from the offshore of Busan was washed with clean water three to four times to remove salts and impurities, dried in a freeze dryer after washing, washing and dehydration, and then powdered with a food grinder to prepare a green powder.

본 발명의 파래 추출물 제조Preparation of green extract of the present invention

3구 플라스크에 5L의 증류수와 파래 분말 200g을 침지시키고 상온에서 4시간 동안 교반하여 추출하였다. 그 후 원심분리(3,000rpm, 4℃, 30분)하여 상층액을 분리하였으며, 상층액의 3배 부피의 에탄올을 첨가하여 저온에서 24시간 동안 반응시켜 당을 가라앉혔다. 그 후 감압 여과하여 당을 제거한 후, 여과액을 감압 농축하였다. 원심분리 후 얻어진 잔사를 같은 방법으로 한 번 더 추출하고, 농축시켰다. 농축물을 증류수에 녹이고 암모늄 설페이트를 첨가하여 포화시키는 방법으로 24시간동안 단백질을 침전시켰다. 원심분리(3,000rpm, 4℃, 20분)하여 침전된 단백질만 분리하고, 침전된 단백질 액체에 남아있는 암모늄 설페이트를 제거하기 위하여 투석막을 이용하여 48시간동안 증류수 내에서 교반하였다. 이후 최종적으로 얻은 파래 추출물을 동결 건조하여 분말화 하였다. 도 1은 본 발명에 따른 파래 추출물의 제조 과정을 간략화한 공정도이다.5 L of distilled water and 200 g of green powder were immersed in a three-necked flask and extracted by stirring at room temperature for 4 hours. Thereafter, the supernatant was separated by centrifugation (3,000 rpm, 4 ° C., 30 minutes), and ethanol in three times the volume of the supernatant was added to react with sugar at low temperature for 24 hours. After filtration under reduced pressure to remove sugar, the filtrate was concentrated under reduced pressure. The residue obtained after centrifugation was extracted once more in the same manner and concentrated. The concentrate was dissolved in distilled water and protein was precipitated for 24 hours by adding ammonium sulfate and saturating. The precipitated protein was separated only by centrifugation (3,000 rpm, 4 ° C., 20 minutes), and stirred in distilled water for 48 hours using a dialysis membrane to remove ammonium sulfate remaining in the precipitated protein liquid. After that, finally obtained green extract was lyophilized and powdered. Figure 1 is a simplified process chart of the production process of green onion extract according to the present invention.

비교예Comparative example

파래 증류수 추출물의 제조Preparation of Green Distilled Water Extract

본 발명의 파래 추출물과의 세포활성 비교를 위하여 추출 용매로서 증류수만을 사용하여 파래 추출물을 제조하였다. 먼저 3구 플라스크에 5L의 증류수와 파래 분말 200g을 침지시키고 상온에서 4시간 동안 교반하여 추출하였다. 그 후 원심분리(3,000rpm, 4℃, 30분)하여 상층액을 분리하였으며, 얻어진 상층액을 동결 건조하여 분말화 한 후 실험에 사용하였다.In order to compare the cell activity with the extract of the present invention, the extract was prepared using only distilled water as the extraction solvent. First, 5 L of distilled water and 200 g of green powder were immersed in a three-necked flask, and extracted by stirring at room temperature for 4 hours. Thereafter, the supernatant was separated by centrifugation (3,000 rpm, 4 ° C., 30 minutes), and the obtained supernatant was lyophilized to be powdered and used for experiments.

실험예 1. 본 발명의 파래 추출물의 세포 활성 평가 Experimental Example 1. Evaluation of cell activity of the green extract of the present invention

본 발명에 따른 파래 추출물의 근조직 생성 촉진 효과를 알아보기 위하여, 근아세포(myoblast, skeletal muscle, L6 cell)를 ATCC(Americal Type Culture Collection)에서 분양받아 배양하였다. 실험을 위해 세포는 1X106 cells/well의 수준으로 하여 96 well 플레이트에 배양하였으며, 배지는 10% FBS를 포함한 DMEM(Dulbecco's Modified Eagle's Medium)을 사용하였다. 10% FBS를 함유하는 DMEM에서 24시간 배양하여 플레이트 표면적 60%정도 배양되면, 실시예에서 제조한 파래 추출물이 함유된 serum free DMEM과 파래 증류수 추출물이 함유된 serum free DMEM으로 교체하여 24시간 배양하였다. 24시간 후 세포활성을 측정하기 위하여 배지를 제거하고 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxiphenyl)-2- (4-sulfophenyl)-2H-tetrazolium (MTS, promega, USA) 용액을 첨가하여 30분간 반응한 뒤 490nm에서 ELISA plate reader 기기를 이용하여 흡광도를 측정하였다. 근조직 생성 촉진 정도는 파래 추출물을 처리하지 않은 대조군의 흡광 강도를 기준으로 하여 백분율로 계산하여 표기하였다. 세포활성을 측정한 결과를 도 2로 나타내었으며, 본 발명의 파래 추출물의 경우 세포의 활성을 촉진시키는 결과가 확인되었으나, 증류수만을 이용하여 추출한 파래 증류수 추출물의 경우 세포의 활성에 영향을 주지 않는 다는 점을 확인하였다.In order to investigate the effect of promoting the muscle tissue production of the green extract according to the present invention, myoblasts (myoblast, skeletal muscle, L6 cells) were cultured by being sold in the ATCC (Americal Type Culture Collection). For the experiment, cells were cultured in 96 well plates at the level of 1 × 10 6 cells / well, and DMEM (Dulbecco's Modified Eagle's Medium) containing 10% FBS was used as a medium. After 24 hours of incubation in DMEM containing 10% FBS and about 60% of the surface area of the plate, serum free DMEM containing green sea extract prepared in Example and serum free DMEM containing green distilled water extract were incubated for 24 hours. . After 24 hours, the medium was removed to measure cellular activity and 3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxiphenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS, promega , USA) solution was added for 30 minutes and the absorbance was measured using an ELISA plate reader at 490 nm. The degree of muscle tissue promotion was calculated and expressed as a percentage based on the absorbance intensity of the control group not treated with the green extract. The results of measuring the cell activity are shown in FIG. 2, and the results of promoting cell activity in the case of the green leaf extract of the present invention were confirmed, but the distilled water extract extracted using only distilled water does not affect the cell activity. The point was confirmed.

세포생존율(Cell viability, %) = (추출물 처리군의 흡광도/대조군의 흡광도)X100Cell viability (%) = (absorbance of extract treated group / absorbance of control group) X100

실험예 2. 웨스턴 블롯팅을 통한 본 발명 파래 추출물의 근조직 생성 촉진 효능 분석Experimental Example 2. Analysis of the muscle tissue production promoting effect of the present invention green extract by Western blotting

본 발명의 파래 추출물의 근조직 생성 촉진 효능을 확인하고자 세포성장 촉진인자인 Insulin-like growth factor-1 (IGF-1)과 그 하위 신호전달에 대한 확인 실험을 진행하였다. Ø100 플래이트에 배양된 근아세포를 RIPA 라이시스 완충액(2μg/ml 펩스타틴, 2g/ml Na3VO4, 2μg/ml NaF, 1μg/ml 아프로티닌, 5μg/ml 류펩틴, 10μg/ml 페닐메틸설포닐플루오라이드)속에서 균질화하고 원심분리(12,000rpm, 4℃, 20분)하여 상층액을 회수하였다. 단백질 농도는 BCA 단백질 분석 키트로 측정하였고, 단백질 양을 50μg/레인으로 동일하게 취하여 5X 시료 완충액과 섞어 수조에서 끓이고 7.5%, 10% 및 12.5% SDS-PAGE 겔에 웨스턴 블롯하였다. 표준 분자량은 이중 색상 마커(dual color marker)를 사용하였고, PVDF 멤브레인(Millipore, USA)으로 전달하였다. 멤브레인은 1% 소혈청알부민(BSA)/TBS-T로 블락(Block)하였고, 1차 항체에서 2시간 동안 상온 반응시키고, TBS-T로 15분간 2회 세척한 후 2차 항체를 1:10,000-5,000 비율로 희석하여 1시간 반응시켰다. 반응시킨 멤브레인을 TBS-T로 15분간 2회 세척한 후, uper Signal West Pico Luminol/Enhancer solution 와 Super Signal West Pico Stable Peroxide solution (Rockford IL, USA)을 사용하여 형광 젤 이미지 분석장치 (Azure biosystems)로 현상한 후 스캔하여 나온 밴드로 단백질 발현 수준을 확인하였다. In order to confirm the effect of promoting the muscle tissue production of the green extract of the present invention was carried out to confirm the cell growth promoting factor Insulin-like growth factor-1 (IGF-1) and its lower signaling. Myoblasts cultured on Ø100 plate were treated with RIPA Lysis buffer (2 μg / ml pepstatin, 2 g / ml Na 3 VO 4 , 2 μg / ml NaF, 1 μg / ml aprotinin, 5 μg / ml leupetin, 10 μg / ml phenylmethylsulphur) Homogenized in phenylfluoride) and centrifuged (12,000 rpm, 4 ℃, 20 minutes) to recover the supernatant. Protein concentration was measured with a BCA protein assay kit, and the protein amount was taken equally at 50 μg / lane, mixed with 5X sample buffer, boiled in a water bath and western blotted on 7.5%, 10% and 12.5% SDS-PAGE gels. Standard molecular weights were used with dual color markers and delivered to PVDF membranes (Millipore, USA). The membrane was blocked with 1% bovine serum albumin (BSA) / TBS-T, reacted at room temperature in the primary antibody for 2 hours, washed twice with TBS-T for 15 minutes, and then the secondary antibody was 1: 10,000. Dilution at -5,000 ratio was carried out for 1 hour. The reaction membrane was washed twice with TBS-T for 15 minutes, followed by fluorescent gel image analyzer using uper Signal West Pico Luminol / Enhancer solution and Super Signal West Pico Stable Peroxide solution (Rockford IL, USA). After developing, the protein bands were checked by scanning bands.

본 실험예에서는 IGF-1 경로의 IGF-1R의 인산화와 하위 신호경로 단백질의 발현량을 확인하였으며, 이를 도 3 및 4로 나타내었다. 도 3에서 확인한 바와 같이, 대조군에 비해 파래 추출물 처리군(EL-GP)에서의 IGF-1R 단백질의 인산화가 증가한 것으로 나타났으며 관련된 단백질인 shc, PY99의 발현량이 증가한 것으로 확인되었다. 이는 세포의 대사, 성장 및 분화에 본 발명의 파래 추출물이 효과를 나타낸 것으로 판단된다. 도 4에서 확인한 바와 같이, IGF로 유도되어져 세포의 증식을 촉진하는 Ras/Raf 단백질의 발현과 MEK, ERK 단백질의 인산화 역시 대조군에 비해 본 발명의 파래 추출물 처리군이 증가하는 것으로 나타났다. 이로부터 본 발명의 파래 추출물이 근조직의 생성 촉진에 관여하는 것으로 판단된다.In this experimental example, the phosphorylation of IGF-1R of the IGF-1 pathway and the expression level of the lower signal pathway protein were confirmed, which are shown in FIGS. 3 and 4. As shown in FIG. 3, the phosphorylation of IGF-1R protein was increased in the green extract treatment group (EL-GP) compared to the control group, and the expression levels of shc and PY99, which are related proteins, were increased. It is believed that the green extract of the present invention has an effect on the metabolism, growth and differentiation of cells. As shown in FIG. 4, the expression of Ras / Raf protein and the phosphorylation of MEK and ERK proteins, which are induced by IGF to promote cell proliferation, were also increased in the green extract treatment group of the present invention compared to the control group. From this it is judged that the green extract of the present invention is involved in promoting the production of muscle tissue.

Claims (4)

1) 파래를 증류수로 추출하는 것;
2) 상기 추출물을 원심분리하여 상층액을 분리하는 것;
3) 상기 상층액에 2 내지 4배 부피의 에탄올을 가하고 당을 가라앉히는 것; 및
4) 가라앉힌 당을 여과하여 제거한 후 여과액을 감압 농축하는 것을 포함하는 방법으로 수득한 파래 추출물을 포함하는 근조직 생성 촉진용 조성물.
1) extracting the seaweed with distilled water;
2) separating the supernatant by centrifuging the extract;
3) adding 2-4 times the volume of ethanol to the supernatant to settle the sugar; And
4) A composition for promoting muscle tissue production comprising a green leaf extract obtained by filtering the submerged sugar and then removing the filtrate under reduced pressure.
제1항에 있어서, 상기 추출 방법은 5) 얻어진 추출물을 증류수에 녹이고 암모늄 설페이트 또는 아세톤을 첨가하여 침전물을 수득하는 것을 더 포함하는 것인 근조직 생성 촉진용 조성물. The composition for promoting muscle tissue production according to claim 1, wherein the extraction method further comprises dissolving the obtained extract in distilled water and obtaining a precipitate by adding ammonium sulfate or acetone. 제1항에 있어서, 상기 1) 단계에서의 파래는 파래 분말인 근조직 생성 촉진용 조성물. The composition for promoting muscle tissue production according to claim 1, wherein the green onion in step 1) is a green powder. 제1항에 있어서, 상기 3) 단계에서는 에탄올을 상층액의 3배 부피로 사용하는 것인 근조직 생성 촉진용 조성물.
According to claim 1, wherein in step 3) ethanol is used as a three times volume of the supernatant composition for promoting muscle tissue production.
KR1020180066105A 2018-06-08 2018-06-08 A Composition Comprising Extract of Enteromorpha for promoting muscle tissue production KR102082196B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020180066105A KR102082196B1 (en) 2018-06-08 2018-06-08 A Composition Comprising Extract of Enteromorpha for promoting muscle tissue production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180066105A KR102082196B1 (en) 2018-06-08 2018-06-08 A Composition Comprising Extract of Enteromorpha for promoting muscle tissue production

Publications (2)

Publication Number Publication Date
KR20190139521A true KR20190139521A (en) 2019-12-18
KR102082196B1 KR102082196B1 (en) 2020-02-27

Family

ID=69052482

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180066105A KR102082196B1 (en) 2018-06-08 2018-06-08 A Composition Comprising Extract of Enteromorpha for promoting muscle tissue production

Country Status (1)

Country Link
KR (1) KR102082196B1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102919622A (en) * 2012-11-28 2013-02-13 中国水产科学研究院黄海水产研究所 Application of enteromorpha prolifera serving as toner in litopenaeus vannamei feed
KR20130094630A (en) * 2012-02-16 2013-08-26 제주대학교 산학협력단 A composition comprising the extract of ulva fasciata delile for preventing and treating inflammatory diseases
CN104957363A (en) * 2015-07-20 2015-10-07 青岛海之星生物科技有限公司 High-quality compound feed for adult turbots and preparation method thereof
CN105028944A (en) * 2015-09-22 2015-11-11 烟台金德生物有限公司 Compound feed for chicken breed
CN106418076A (en) * 2016-09-28 2017-02-22 国家海洋局北海环境监测中心 Preparation method of enteromorpha health care beverage
KR20170124473A (en) * 2016-05-02 2017-11-10 연세대학교 산학협력단 Composition for enhancing muscle function and exercise capacity comprising Vigna angularis
KR20170132705A (en) * 2015-05-26 2017-12-04 (주)앗코스텍 Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130094630A (en) * 2012-02-16 2013-08-26 제주대학교 산학협력단 A composition comprising the extract of ulva fasciata delile for preventing and treating inflammatory diseases
CN102919622A (en) * 2012-11-28 2013-02-13 中国水产科学研究院黄海水产研究所 Application of enteromorpha prolifera serving as toner in litopenaeus vannamei feed
KR20170132705A (en) * 2015-05-26 2017-12-04 (주)앗코스텍 Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions
JP2018524398A (en) * 2015-05-26 2018-08-30 エーエーティー コステック カンパニー リミテッド Composition for preventing, improving or treating muscle diseases or improving muscle function
CN104957363A (en) * 2015-07-20 2015-10-07 青岛海之星生物科技有限公司 High-quality compound feed for adult turbots and preparation method thereof
CN105028944A (en) * 2015-09-22 2015-11-11 烟台金德生物有限公司 Compound feed for chicken breed
KR20170124473A (en) * 2016-05-02 2017-11-10 연세대학교 산학협력단 Composition for enhancing muscle function and exercise capacity comprising Vigna angularis
CN106418076A (en) * 2016-09-28 2017-02-22 国家海洋局北海环境监测中心 Preparation method of enteromorpha health care beverage

Also Published As

Publication number Publication date
KR102082196B1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CN114230635B (en) High-activity selenium-rich oyster antioxidant peptide and application thereof
JP2023062127A (en) Refining of phycobiliprotein
US20120164076A1 (en) Methods of treatment using thymus-derived compositions
US20210361715A1 (en) Use of exosome derived from mesenchymal stem cells co-cultured with melatonin in prevention and treatment of chronic kidney disease
RU2018106915A (en) METHOD FOR EXTRACTION OF SAPONINS FROM AGRICULTURAL PRODUCTS
KR101189605B1 (en) White pleuropterus multiflorus and phlomis umbrosa extract for promoting insulin-like growth factor secretion and bone framework growth, and method for producing the same
EP1098656B1 (en) Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof
CN111808793A (en) High-activity and high-purity mitochondria extraction and purification method
KR102082196B1 (en) A Composition Comprising Extract of Enteromorpha for promoting muscle tissue production
CN109294980A (en) Root of kirilow rhodiola and rhodioside are divided into the application in cardiac-like muscle cell in stem cell directional
Fantozzi Grape seed: A potential source of protein
CN113698454B (en) Walnut meal acetylcholine esterase inhibitory peptide as well as preparation method and application thereof
BR112020023485A2 (en) METHODS FOR PREPARING A RECOMBINANT OR HUMAN INSULIN PRECURSOR OF THE SAME, RECOMBINANT HUMAN INSULIN OR ANALOG OF THE SAME AND ACILLATE INSULIN ANALOG
US1469994A (en) Extract obtainable from the mammalian pancreas or from the related glands in fishes, useful in the treatment of diabetes mellitus, and a method of preparing it
CN109771449A (en) A kind of Hijiki polysaccharide and its application with promotion wound healing effect
CN113087773B (en) Yak bone peptide with blood sugar reducing and antioxidant functions and preparation method thereof
CN114874291A (en) Artificial tiger bone polypeptide and preparation method and application thereof
CN107641154B (en) Squid bioactive peptide and preparation method thereof
US3267090A (en) Viscumic acid and salts thereof
CN110051732A (en) The preparation method of Semen Plantaginis extract and its application in terms of preparing treatment/prevention high lithemia related disease medicine/health product
CN113735988B (en) Extraction method of lentinan
Ofem et al. Viscum album (mistletoe) extract prevents changes in levels of red blood cells, PCV, Hb, serum proteins and ESR in high salt-fed rats
SU1625871A1 (en) Method of free amino acids isolation from plant tissue
CN115947778B (en) Small peptide with lipid-lowering activity, preparation method and application thereof
KR101375052B1 (en) Process for extracting propolis efficiency element having improved dispersibility in water

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right